About the company 

Using the full potential of gene editing, JURA Bio is creating a novel therapeutic platform of curative, definitive, cell-based therapies against autoimmune diseases. The company has developed a disruptive treatment approach that is harnessing the body’s immune system to neutralize pathologic cells.

About the solution 

Autoimmune diseases—a group of more than 80 diseases, including Crohn’s, ulcerative colitis, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis, and scleroderma—burden individuals with lifetime health challenges and more than $100 billion annually in treatment costs. In a first clinical proof-of-concept, JURA Bio is developing allogeneic, off-the-shelf CAR-T cells against progressive forms of multiple sclerosis (PPMS).

CAR-T is for more than just oncology. Using the full potential of gene editing, JURA Bio is creating a therapeutic platform for cell-based therapies that are not just disease-modifying, but curative and definitive.